MedTrace Logo

Study of an Investigational Pneumococcal Vaccine in Healthy Adult Volunteers

NCT01444001 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2011-09-30

No results posted yet for this study

Summary

This study was designed to evaluate the safety, tolerability, and immunogenicity of three doses of an investigational pneumococcal vaccine in healthy adult volunteers.

Primary Objective:

* To evaluate the safety and tolerability of an investigational Pneumococcal vaccine.

Conditions

  • Pneumococcal Infections
  • Pneumococcal Pneumonia

Interventions

BIOLOGICAL

Pneumococcal Vaccine

0.5 mL, intramuscular

BIOLOGICAL

Pneumococcal Vaccine

0.5 mL, intramuscular

BIOLOGICAL

Pneumococcal Vaccine

0.5 mL, intramuscular

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Sanofi Pasteur Ltd.

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2007-08-31
Completion
2007-08-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01444001 on ClinicalTrials.gov